MedTrace Logo

Proof of Concept for Real-time Multicentric Monitoring of MRD by PET and ctDNA in Aggressive B-Cell Lymphomas

NCT07514715 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 129

Last updated 2026-04-13

No results posted yet for this study

Summary

RT4 (REAL TIME TAILORED THERAPY) study was designed as a national, multicenter proof of concept aiming to demonstrate the technical and operational capacity of the French Connect network and the Positron Emission Tomography (PET) review network to ensure, within a coordinated framework, real time MINIMAL RESIDUAL DISEASE (MRD) monitoring through ctDNA analysis and centralized review of PET imaging.

Conditions

  • Aggressive B-cell Lymphomas

Interventions

OTHER

blood test

Three blood tests will be performed (one before treatment, one at mid treatment, and one at the end of treatment) for ctDNA analysis.

Sponsors & Collaborators

  • The Lymphoma Academic Research Organisation

    lead OTHER

Principal Investigators

  • Vincent CAMUS, Dr · CENTRE HENRI BECQUEREL - Service Hématologie

  • Cédric ROSSI, Pr · CHU DIJON BOURGOGNE - Service Hématologie Clinique

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-31
Primary Completion
2028-10-01
Completion
2028-10-01

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07514715 on ClinicalTrials.gov